Investor relations

With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.

We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.

Johan Spetz

CFO and Head of Investor Relations Send Email

The Share

See More

Press Releases

Sedana Medical reports topline results from phase 3 paediatric IsoCOMFORT study


Sedana Medical AB (publ) today announces that the primary endpoint of its Phase 3 IsoCOMFORT study w…

Report from Sedana Medical AB’s annual general meeting on May 16, 2023


Sedana Medical AB’s annual general meeting was held on Tuesday, May 16, 2023. The main resolutions p…

Sedana Medical AB’s Interim report January-March 2023


Back to growth

View All Press Releases

Financial Calendar

Year-End Report 2022 16 February 2023 07:00
Annual Report 2022 03 April 2023 00:00

See More